Equities research analysts expect that Celsion Co. (NASDAQ:CLSN) will report earnings per share of ($0.31) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Celsion’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.32). Celsion reported earnings of ($1.96) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 84.2%. The business is scheduled to report its next quarterly earnings report on Thursday, March 15th.

According to Zacks, analysts expect that Celsion will report full year earnings of ($2.46) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($1.15) per share, with EPS estimates ranging from ($1.21) to ($1.08). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Celsion.

A number of equities research analysts have recently weighed in on the company. ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target for the company. Finally, Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Celsion currently has a consensus rating of “Buy” and a consensus price target of $11.90.

A hedge fund recently bought a new stake in Celsion stock. Virtu Financial LLC purchased a new position in shares of Celsion Co. (NASDAQ:CLSN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 42,018 shares of the biotechnology company’s stock, valued at approximately $113,000. Virtu Financial LLC owned 0.24% of Celsion as of its most recent filing with the Securities and Exchange Commission. 3.84% of the stock is owned by institutional investors and hedge funds.

Celsion (CLSN) traded up $0.12 during mid-day trading on Friday, reaching $2.37. The company’s stock had a trading volume of 95,549 shares, compared to its average volume of 354,812. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06. The stock has a market cap of $39.90, a P/E ratio of -0.40 and a beta of 1.80.

COPYRIGHT VIOLATION WARNING: “” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/03/05/1807231.html.

About Celsion

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).

Get a free copy of the Zacks research report on Celsion (CLSN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.